Drug­mak­ers sub­mit coun­terof­fers as part of first round of drug price ne­go­ti­a­tions

The Biden Ad­min­is­tra­tion on Mon­day con­tin­ued to tout its ef­forts to low­er drug prices, not­ing in a state­ment ahead of a like­ly drug-pric­ing-heavy State of the Union on Thurs­day that man­u­fac­tur­ers for all 10 drugs se­lect­ed for ne­go­ti­a­tions have sub­mit­ted coun­terof­fers to CMS.

The ad­min­is­tra­tion is fight­ing ef­forts to over­turn the drug pric­ing pro­vi­sions from the In­fla­tion Re­duc­tion Act in court — As­traZeneca lost a key case on Fri­day — as well as in Con­gress. Last Au­gust, CMS un­veiled the first 10 drugs that will be sub­ject to price ne­go­ti­a­tions un­der the IRA, in­clud­ing sev­er­al that may face com­pe­ti­tion from gener­ics be­fore the ne­go­ti­at­ed prices take ef­fect in 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER